Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of bb2121 (idecabtagene vicleucel) in relapsed and refractory multiple myeloma
2017-002245-29Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Overall response rate (ORR). Started Dec 2017; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-002245-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002245-29.